Praluent Cost in Alabama 2026: Cash Price, Insurance, Medicaid and Compounding

What Is Praluent and Why Does It Cost So Much?

Praluent is the brand name for alirocumab, a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). Blocking PCSK9 keeps LDL receptors on liver cells active longer, which pulls more LDL cholesterol out of circulation. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering on top of maximally tolerated statin therapy [1].

Biologics like alirocumab are manufactured through living cell cultures, a process far more expensive than synthesizing a small-molecule pill. That manufacturing cost, combined with patent protection held jointly by Regeneron and Sanofi, is the primary driver behind the $580 per month list price Alabamians see at the pharmacy counter in 2026.

ODYSSEY OUTCOMES, a placebo-controlled trial of 18,924 patients with recent acute coronary syndrome, found that alirocumab 75-150 mg every 2 weeks reduced LDL-C by 54.7% versus placebo at 48 weeks and cut the composite of major adverse cardiovascular events (MACE) by 15% (hazard ratio 0.85; 95% CI 0.78-0.93; P<0.001) [2]. That evidence base is strong. The price, for many patients in Alabama, is not manageable without assistance.

Alabama Retail Cash Price for Praluent in 2026

The sticker price at Alabama retail pharmacies is approximately $580 per month in 2026 for either the 75 mg/mL or 150 mg/mL pre-filled pen. That figure applies whether you are filling a 2-week supply (two pens per month) or the 300 mg monthly dose (two 150 mg pens given on the same day, once a month). No meaningful geographic variation exists between Birmingham, Huntsville, Montgomery, or Mobile for brand-name Praluent. It is a fixed wholesale acquisition cost product.

Paying $580 monthly out of pocket, over a year, means $6 to 960 in drug costs alone, before any office visit, laboratory monitoring, or cardiology follow-up. For context, the median household income in Alabama is approximately $56,929 per year [3]. A drug consuming more than 12% of median household income before taxes is, for the majority of uninsured or underinsured Alabamians, simply not accessible at list price.

The 90-day supply option does not provide a meaningful discount on alirocumab the way it does for generics. Expect roughly $1,740 for a 90-day fill at most Alabama retail chains.

Does Alabama Medicaid Cover Praluent?

Alabama Medicaid does not cover Praluent (alirocumab) as of 2026. The Alabama Medicaid Agency's preferred drug list (PDL) does not include alirocumab, and no non-preferred exception pathway currently offers reliable access for ASCVD or HeFH indications. Patients enrolled in Alabama Medicaid who require PCSK9 inhibition may petition for a prior authorization exception, but approvals are rare and inconsistent.

The American College of Cardiology and American Heart Association 2022 Guideline on Cardiovascular Risk Reduction states: "In patients with clinical ASCVD on maximally tolerated statin therapy in whom LDL-C remains above 70 mg/dL, PCSK9 inhibitors are recommended (Class I, Level A)" [4]. That guideline-level recommendation has not yet translated into Medicaid coverage in Alabama.

Evolocumab (Repatha), the competing PCSK9 inhibitor from Amgen, faces the same Alabama Medicaid exclusion. Patients on Alabama Medicaid who need a PCSK9 inhibitor are generally left choosing between the manufacturer patient assistance program, 503A compounding, or going without.

Commercial Insurance Coverage in Alabama

Commercial plan coverage varies widely, but most major carriers operating in Alabama (Blue Cross and Blue Shield of Alabama, UnitedHealthcare, Cigna, Aetna, Humana) place Praluent on a Tier 4 or Tier 5 specialty formulary tier. Tier 4-5 copays commonly run between $150 and $400 per month even after insurance pays its share.

Prior authorization (PA) is nearly universal. Typical PA requirements in Alabama commercial plans include:

• Documentation of an LDL-C above 70 mg/dL despite maximally tolerated statin therapy for at least 3 months
• Confirmed diagnosis of HeFH (genetic or clinical criteria) or established ASCVD
• Evidence that the prescriber has considered or trialed ezetimibe first
• Cardiology or endocrinology specialist involvement (some plans require it, others accept primary care)

Step therapy is a second hurdle. Several plans require a documented trial of ezetimibe (generic, roughly $15-30 per month) before approving alirocumab. Ezetimibe reduces LDL-C by approximately 18-20% on average, which is insufficient for many ASCVD patients already on high-intensity statins who need 50%+ LDL reduction [5].

If your commercial plan approves Praluent, the Regeneron / Sanofi Praluent MyWay savings card can reduce your copay to as low as $0 per month (see the savings card section below).

The Regeneron/Sanofi Praluent Savings Card: How It Works in Alabama

The Praluent MyWay copay card is available to commercially insured patients in Alabama. It is not valid for patients whose primary coverage is Medicare, Medicaid, TRICARE, or any other federal or state government-funded program.

Eligible patients can pay as little as $0 per month copay, with the manufacturer covering the remainder up to a program maximum. Enrollment takes roughly 5 minutes at the Praluent website or by calling 1-844-PRALUENT. Your prescribing provider can also enroll you through their electronic health record hub.

Key conditions for the Alabama patient:

1. You must have a valid commercial insurance prescription benefit.
2. Your insurance must have approved the prescription (or be in the PA process).
3. The savings card does not reduce the gross list price. It covers the gap between your plan's allowed amount and your copay requirement.
4. The card has an annual maximum benefit. For 2026 the program cap is approximately $7,200 per calendar year, which, at $580 list price, covers roughly 12 months of copay exposure for most Tier 4 plans.

Patients who are Medicare Part D beneficiaries should ask their oncologist or cardiologist about the separately administered Praluent patient assistance program (PAP), which can provide free drug to qualifying low-income Medicare patients.

Compounded Alirocumab in Alabama: Is It Legal?

Yes. Compounded alirocumab is legally available in Alabama through licensed 503A compounding pharmacies as of 2026.

Section 503A of the Federal Food, Drug and Cosmetic Act permits state-licensed pharmacies to compound drugs on a patient-specific, prescription basis. Alabama Board of Pharmacy regulations permit 503A pharmacies to compound drug products, including biologics, when a valid prescription is presented and the compounding is not commercially available at an appropriate dose, or when the commercially available product is inaccessible to the patient due to cost or formulary exclusion [6].

The compound is prepared from alirocumab bulk active pharmaceutical ingredient (API) sourced from an FDA-registered supplier. It is formulated as a subcutaneous injection and dispensed in patient-specific quantities. The compounded version is not FDA-approved. However, when prepared by a licensed, USP-compliant 503A pharmacy under a physician's prescription, it is legal under both federal and Alabama state law.

HealthRX Compounded vs. Brand Alirocumab Decision Framework for Alabama Patients

| Patient Situation | Recommended Path | |---|---| | Commercially insured, PA approved, copay <$50 | Brand Praluent with MyWay card | | Commercially insured, PA denied after appeal | Compounded alirocumab via 503A + appeal simultaneously | | Alabama Medicaid only | Compounded alirocumab via 503A (Medicaid won't cover brand) | | Medicare Part D, meets PAP income criteria | Praluent PAP (free brand drug) | | Uninsured, income above PAP threshold | Compounded alirocumab via 503A | | Cash-pay, wants brand for any reason | ~$580/month retail, no subsidy available |

Compounded alirocumab at 503A pharmacies currently costs patients $0 to $120 per month depending on the pharmacy and whether the compounding is covered under a telehealth membership plan. Several telehealth platforms operating in Alabama include compounded PCSK9 inhibitor access in their cardiovascular care programs at no additional drug cost above the monthly membership fee.

It is worth being specific about quality considerations. Not all 503A pharmacies hold the same USP <797> (sterile compounding) accreditation. Before filling compounded alirocumab, confirm the pharmacy holds current PCAB (Pharmacy Compounding Accreditation Board) accreditation and that the batch was tested for sterility and potency by a third-party analytical laboratory.

How to Get Praluent via Telehealth in Alabama

Telehealth prescribing of Praluent is fully legal in Alabama. Following the Alabama Telehealth Act (Act 2021-446) and subsequent regulatory updates, licensed Alabama physicians and advanced practice providers may prescribe controlled and non-controlled prescription medications via synchronous telehealth visits without a prior in-person encounter, provided an appropriate clinical evaluation occurs [7].

For alirocumab specifically, a telehealth prescriber should complete:

• Review of lipid panel (LDL-C, total cholesterol, HDL-C, triglycerides) within the past 6 months
• Confirmation of statin therapy status and documented intolerance if applicable
• Cardiovascular risk stratification (ASCVD 10-year risk calculator, or documented HeFH)
• Review of relevant comorbidities (CKD, diabetes, hypertension)

The visit typically takes 20-30 minutes. HealthRX clinicians operating in Alabama can order the necessary lipid labs before the visit through partnered lab draw sites or ask patients to upload recent results. A prescription for brand Praluent or compounded alirocumab can be sent to an Alabama-licensed pharmacy the same day.

Telehealth prescribing also simplifies the prior authorization process for commercially insured patients. Several telehealth platforms have dedicated PA specialists who submit insurance appeals on the patient's behalf, often resolving PA requests in 5-10 business days.

Who Qualifies for Praluent in Alabama?

FDA labeling and ACC/AHA guidelines define the patient population. Adults with HeFH or established ASCVD whose LDL-C remains above 70 mg/dL despite maximally tolerated statin therapy are the core indication [1]. The starting dose is 75 mg subcutaneously every 2 weeks. If the LDL-C response at 4-8 weeks is inadequate, the dose may be titrated to 150 mg every 2 weeks. For patients who prefer a monthly dosing schedule, 300 mg (two 150 mg injections on the same day) every 4 weeks produces comparable LDL lowering [1].

The 2022 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction specifies: "PCSK9 inhibitors should be considered in very high-risk ASCVD patients with LDL-C persistently above 70 mg/dL on maximally tolerated lipid-lowering therapy, including high-intensity statins and ezetimibe" [4]. Alabama patients meeting that definition have a strong clinical case for insurance prior authorization and, if denied, for 503A-compounded access.

Patients with statin intolerance also qualify. ODYSSEY ALTERNATIVE (N=314) showed alirocumab reduced LDL-C by 45% in statin-intolerant patients compared to 0.6% with ezetimibe at 24 weeks (P<0.001), with a lower rate of muscle-related adverse events than atorvastatin rechallenge [8].

Comparing PCSK9 Inhibitors Available in Alabama

Alirocumab (Praluent) and evolocumab (Repatha) are the two FDA-approved PCSK9 inhibitors available in Alabama. Inclisiran (Leqvio), a small interfering RNA that reduces PCSK9 synthesis rather than blocking the protein, became FDA-approved in December 2021 and is administered in-office twice yearly [9]. Each has distinct cost and access dynamics.

Evolocumab list price is similar to alirocumab, approximately $560-590 per month in Alabama. Inclisiran's twice-yearly in-office dosing eliminates adherence friction but adds an administration cost per visit. Head-to-head LDL-lowering is comparable across the three agents at approximately 50-60% reduction from baseline on maximally tolerated statin therapy.

For Alabama patients navigating cost, the choice often comes down to which agent their commercial plan has placed on a lower formulary tier, or which compounded version is available through their preferred 503A pharmacy. Both alirocumab and evolocumab APIs are available from FDA-registered suppliers for 503A compounding.

Side Effects and Monitoring Relevant to Alabama Prescribers

Alirocumab is well tolerated. The most common adverse effects in clinical trials were injection site reactions (7.2% vs. 5.1% placebo), nasopharyngitis, and upper respiratory infection [1]. Neurocognitive events were a theoretical concern in early trials; ODYSSEY OUTCOMES found no statistically significant difference in neurocognitive events between alirocumab and placebo over a median 2.8-year follow-up [2].

Patients self-injecting at home need:

• Proper sharps disposal (Alabama has sharps mail-back programs through several retail chains)
• Refrigeration at 36-46°F (2-8°C); pens may be stored at room temperature up to 77°F for up to 30 days
• Injection site rotation (thigh, abdomen, upper arm)

Lipid panel monitoring at 4-8 weeks after dose initiation or titration confirms therapeutic response. Annual monitoring is appropriate for stable patients. No hepatic or renal dose adjustments are required for mild-to-moderate impairment [1].

Step-by-Step: Getting the Lowest Praluent Price in Alabama

Step 1. Request a lipid panel if you do not have results within 6 months. Book a telehealth visit with a HealthRX Alabama-licensed clinician or your cardiologist.

Step 2. Confirm your insurance type. Commercial insurance: proceed to PA. Alabama Medicaid: skip directly to 503A compounding or PAP. Medicare Part D: apply for the Praluent PAP.

Step 3. For commercial insurance, submit PA with documentation of LDL above 70 mg/dL on maximally tolerated statin. Include ASCVD diagnosis codes (ICD-10 I25.10 or Z84.49 for family history of premature atherosclerosis, E78.01 for FH).

Step 4. If PA is approved, enroll in the Praluent MyWay savings card before your first fill to reduce your copay to as low as $0.

Step 5. If PA is denied, file a level-1 appeal immediately and simultaneously request a 503A-compounded alirocumab prescription from your provider. You can switch to brand if the appeal succeeds without restarting clinical protocols.

Step 6. Confirm your 503A pharmacy holds PCAB accreditation and can provide a certificate of analysis (CoA) for sterility and potency for each compounded batch.

Step 7. Schedule a lipid panel recheck 6-8 weeks after your first dose to confirm an LDL-C reduction of at least 40-50% from baseline.

If your LDL-C has not dropped by at least 40% after 8 weeks on 75 mg every 2 weeks, discuss titration to 150 mg every 2 weeks with your prescriber.